OmniAb Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
43.1%projected annual EPS growth
Analyst Coverage
6analysts covering
FY EPS (est.)
-$0.42next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 4 Nov 2026 |
| Q4 2026 Earnings Release | 4 Mar 2027 |
Monitoring Framework
Key Performance Indicators
Active Partners Quarterly107.0
Active Programs Quarterly409.0
OmniAb-derived Programs in Clinical Development or Commercialized Quarterly32.0
Watch Items
- IMVT-1402 Clinical Trial ProgressTrigger: Topline data release in difficult-to-treat rheumatoid arthritis and cutaneous lupus erythematosusAction: Evaluate clinical efficacy and safety profile to assess probability of future milestone and royalty streams.
- Full-Year 2026 Revenue Guidance ExecutionTrigger: Revenue falling below the updated $28 million to $33 million rangeAction: Re-evaluate partner milestone timing assumptions and platform adoption rates.
Research as of 20 Jun 2026